On the efficiency and safety of application of the short course of clobetasol propionate at patients, suffering from psoriasis in the progression phase

Abstract

Research target: to evaluate the efficiency and safety of the application of clobetasol propionate ointment (Cloveit ointment for external application, Jelfa) at 60 patients, suffering from plaque psoriasis of average gravity in dermatosis progression phase. Material and methods. The panel comprises 60 patients, suffering from psoriasis (36 men and 24 women) in the age of 25-55 y.o. (the average age is 35,4 ± 2,1 years). The disease continuity was between 6 months and 12 years. The therapeutic efficiency was evaluated with PASI, PGA indices, аs well as with data of ultrasonographic research. Results. Initiating seven days course of the topical therapy with clobetasol propionate, included in the standard comprehensive treatment, favors the transfer of the psoriatic process in the stabilization phase and is not accompanied with clinical and sub-clinical features of skin atrophy.

Full Text

Об эффективности и безопасности применения клобетазола пропионата коротким курсом у больных псориазом в фазе прогрессирования
×

About the authors

A L BAKULEV

S S KRAVHCHENYA

References

  1. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-1204.
  2. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. JEADV 2012; 3: supp.2: 3-11.
  3. Tsai T.F., Wang T.S., Hung S.T. et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011;63: 40-46.
  4. Augustin M., Glaeske G., Radtke M.A., et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636.
  5. Zheng Y., Danilenko D.M., Valdez P. et al. Interleukin-22, a T(H)17cytokine, mediates IL-23-in-duced dermal inflammation and acanthosis. Nature 2007; 445: 648-651.
  6. Torti D.C., Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57: 1059-1068.
  7. Lowes M.A., Kikuchi T., Fuentes-Duculan J. et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-1211.
  8. Nograles KE, Zaba LC, Shemer A et al. IL-22-producing ‘T22’’ T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009; 123: 1244-1252.
  9. Nograles K.E., Zaba L.C., Guttman-Yassky E. et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159: 1092-1102.
  10. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009; 361:496-509.
  11. Nast A., Boehncke W.H., Mrowietz S. Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012 Mar; 10 Suppl 2:S1-95.
  12. Hsu S., Papp K.A., Lebwohl M.G. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012 Jan;148(1):95-102.
  13. Nast A., Boehncke W.H., Mrowietz U. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2012; Mar; 304(2):87-113.
  14. Korman N.J., Elmets C.A., Menter A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. American Academy of Dermatology Work Group, J Am Acad Dermatol 2011; Jul: 65(1):137-74.
  15. Псориаз. Клинические рекомендации РОДВ. М.: ДЭКС-Пресс 2008; 56.
  16. Кубанова А.А., Кисина В.И., Блатун Л.А. и др. Рациональная фармакотерапия заболеваний кожи и инфекций, передаваемых половым путем. Рук. для практикующих врачей под общ. ред. А.А.Кубановой, В.И.Кисиной. М.: Литтерра, 2005; 882.
  17. Reich K., Bewley A. What is new in topical therapy for psoriasis? JEADV 2011 Jun; 25: Suppl 4:15-20.

Statistics

Views

Abstract: 620

PDF (Russian): 436

Article Metrics

Metrics Loading ...

Dimensions

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2012 BAKULEV A.L., KRAVHCHENYA S.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies